FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

スタックライブラリ

GLP-1 Mimetic Stack

Fat Lossadvanced

75

シナジー

75
Share
ペプチド

2

平均日用量mcg

100,036

レベル

advanced

追加

May 17, 2026

概要

The GLP-1 Mimetic Stack combines the most clinically validated weight loss peptide in modern medicine with an experimental metabolic enhancer. Semaglutide is a GLP-1 receptor agonist that has revolutionized obesity treatment since its approval for weight management (as Wegovy) in 2021. It mimics the incretin hormone GLP-1, which is released by the gut after meals. By activating GLP-1 receptors in the brain''s appetite centers (hypothalamus and brainstem), semaglutide produces profound and sustained appetite suppression. The STEP clinical trials demonstrated average weight loss of 15-17% of body weight over 68 weeks — unprecedented for any pharmacotherapy. Semaglutide''s mechanism extends beyond appetite: it slows gastric emptying (increasing satiety per meal), improves insulin sensitivity, reduces hepatic glucose output, and has demonstrated cardiovascular benefits in the SELECT trial. The starting dose of 0.25mg weekly is titrated upward over 16-20 weeks to the therapeutic dose of 2.4mg, minimizing gastrointestinal side effects (nausea, which is the primary tolerability concern). 5-Amino-1MQ is added to complement semaglutide''s central appetite suppression with peripheral metabolic enhancement. While semaglutide reduces caloric intake, 5-Amino-1MQ increases cellular energy expenditure through NNMT inhibition, potentially mitigating the metabolic adaptation (reduced BMR) that typically accompanies significant caloric restriction. This combination targets both sides of the energy balance equation. The advanced classification reflects that semaglutide requires prescription, has significant GI side effects during titration, and the compounded version availability has changed following the resolution of the FDA shortage declaration in early 2025.

投与プロトコル

Semaglutide

Once per week· subcutaneous

Semaglutideについて詳しく読む →

250 mcg

1回の投与あたり

100,000 mcg

1回の投与あたり

目標と証拠

Appetite suppressionWeight lossMetabolic healthInsulin sensitivityGLP-1
証拠ランク:人間臨床試験(RCT)

警告

  • Semaglutide requires prescription. Compounded versions no longer available (shortage resolved Feb 2025). Brand names: Ozempic, Wegovy. 5-Amino-1MQ is experimental.

Comments

Sign in to join the discussion

注意: このスタックはコミュニティから提出され、研究用のみです。Peptide Contactsは提出されたスタックの安全性や効果性を確認していません。使用するペプチドプロトコル前に常に資格のある医療専門家に相談してください。